We will deliver all district factories by 2020 – Ahomka-Lindsay

Comments

Post a Comment

Popular posts from this blog

Mobile Money Interoperability records more than 4.4million transactions

Image
Mobile Money Interoperability (MMI) recorded more than 4.4 million transactions in its first year of operation. Beginning with just 96,907 transactions in its first month, public usage of the cross network platform grew phenomenally to 422,275 transactions in December last year and 502,873 transactions in May this year. MMI or seamless cross mobile money network transactions became possible in May last year, following a challenge thrown to the Ghana Interbank Payment and Settlement System (GhIPSS), the Telcos and financial institutions by the Vice President, Dr. Mahamudu Bawumia. The Chief Executive Officer of GhIPSS, Archie Hesse in an interview described the MMI initiative as successful. He said it has provided a very efficient way of funds transfer for many people, opening up the mobile money payment platform, enabling people and businesses to use it in different ways. Before MMI came into being, cross network transactions through the ‘token’ system was hovering around 90,000 t...
Read more

Ghana and Novartis sign MoU to make treatment of sickle cell disease accessible

Image
Ghana is set to scale-up the usage of hydroxyurea, a generic drug for the treatment of Sickle Cell Disease (SCD) in all health facilities to reduce the cost of its medications and the burden of treatment on patients and families. This followed a five-year Memorandum of Understanding (MoU) signed between Ghana and Novartis, an international pharmaceutical company, at the World Economic Forum in Davos in January this year to improve the diagnosis and treatment of persons with the disease in Ghana Presently, the first consignment of 5, 600 doses, have been brought into the country and would be distributed in all public health facilities across the country to be sold to patients at a reduced price. Hydroxyurea is a commonly used medicine for patients with sickle cell diseases in developed countries, developed by Novartis and approved for use in adults and children with SCD. Dr Anthony Nsiah- Asare, Director-General of the Ghana Health Service (GHS) said at a press briefing in Accra on ...
Read more